3D In Vitro Human Organ Mimicry Devices for Drug Discovery, Development, and Assessment

Table 4

Summary of recent advancements in gut-on-chip platforms including the type of drug, the applications, the applied cell lines, and the kinetics.

Drug type	Applications	Applied cell lines	Kinetics	Ref(s)
DMOG	Drug interaction; Radiation-g	Caco-2; HUVEC	5 days	[84]
Isofosfamid, verapamil	Pharmacokinetics	Caco-2	11 days	[93]
Midazolam, indomethacin	Pharmacokinetics; Toxicity	PiEC, human myofibroblast, Caco-2	21 days	[94]
Paracetamol	Toxicity	Caco-2, HepG2	14 days	[140]
Mariskat	Efficacy	Caco-2, hIEC	24 days	[141]
Rifampicin, ketoconazole	Pharmacokinetics	HiPCs	34 days	[142]

DMOG: dimethyloxaloyl; Caco-2: colon adenocarcinoma cells; HUVECs: human umbilical vein endothelial cells; PiEC: primary intestinal epithelial cells; HepG2: human hepatocellular carcinoma cells; hIEC: human intestinal epithelial cells; HiPCs: hormone independent prostate cells.